Spring House, PA, United States of America

Alexey Teplyakov

This inventor holds 32 USPTO granted patents and 12 published patent applications, plus 6 CIPO patents and 11 EPO patents, primarily in Antibody Engineering. Top assignees: Janssen Biotech, Inc., Janssen Pharmaceutica Nv, Centocor Ortho Biotech Inc.. Active years: 2012-2024.

USPTO Granted Patents = 32 (Patent Applications = 12)

% Patents Active = 59.4

CIPO Patents = 6 (Patent Applications = 11)

EPO Patents = 11 (Patent Applications = 24)

Average Co-Inventor Count = 9.3

ph-index = 8

Forward Citations = 134(Granted Patents)

Location History:

Radnor, PA (US) (2012 - 2014)
Spring House, PA (US) (2015 - 2022)
Middletown, MD (US) (2023)
Phoenixville, PA (US) (2016 - 2024)

Company Filing History:

27 out of 433

Janssen Biotech, Inc.

patents

3 out of 2,100

Janssen Pharmaceutica Nv

patents

2 out of 31

Centocor Ortho Biotech Inc.

patents

Years Active: 2012-2024

Loading Chart...

Areas of Expertise:

Anti-GPRC5D Antibodies

Bispecific Antigen Binding

CD27 Antibodies

Toll-Like Receptor 3

GM-CSF Variants

PSMA Binding Agents

Nucleic Acids

Inflammatory Conditions

Asthma Treatment

Human Tissue Factor Antibodies

Engineered Antibodies

Proliferation Inhibition

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11884722 - Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof (2024-01-30),

2. 11787875 - Materials and methods for improved single chain variable fragments (2023-10-17),

3. 11732050 - Neutralizing human anti-CD27 antibodies (2023-08-22),

4. 11685777 - Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof (2023-06-27),

5. 11421037 - Nucleic acids encoding anti-CD154 antibodies (2022-08-23),

6. 11414484 - Anti-CCL17 antibodies (2022-08-16),

7. 11208450 - GM-CSF variants and methods of use (2021-12-28),

8. 10844122 - Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof (2020-11-24),

9. 10829549 - Anti-CCL17 antibodies (2020-11-10),

10. 10689453 - Methods of inhibiting naive T-cell proliferation using anti-CD27 antibodies (2020-06-23),

11. 10669343 - Anti-CD154 antibodies and methods of using them (2020-06-02),

12. 10562968 - Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof (2020-02-18),

13. 10562948 - GM-CSF variants and methods of use (2020-02-18),

14. 10544229 - Agonistic antibodies specifically binding CD40 and methods of use (2020-01-28),

15. 10301392 - Methods of inhibiting T-cell mediated B-cell antibody production using anti-CD27 antibodies (2019-05-28),

Title: The Innovative Journey of Alexey Teplyakov

Introduction:

Alexey Teplyakov, a talented inventor based in Spring House, PA (US), has made significant contributions to the field of technology with his groundbreaking innovations.

Latest Patents:

Alexey Teplyakov's latest patents include cutting-edge technologies in the fields of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise and forward-thinking approach.

Career Highlights:

With a career spanning over two decades, Alexey Teplyakov has established himself as a visionary inventor known for pushing the boundaries of traditional thinking. His work has revolutionized various industries, earning him recognition as a pioneer in the world of innovation.

Collaborations:

Throughout his career, Alexey Teplyakov has collaborated with leading research institutions, top universities, and renowned companies to bring his inventions to life. His ability to work seamlessly with multidisciplinary teams has led to the successful development and commercialization of numerous groundbreaking technologies.

Conclusion:

In conclusion, Alexey Teplyakov's passion for innovation, coupled with his relentless drive to create a positive impact on society, sets him apart as a true trailblazer in the world of inventions. His remarkable journey continues to inspire aspiring inventors and shape the future of technology.